Agios Pharmaceuticals, Inc. $AGIO Shares Sold by Edgestream Partners L.P.

Edgestream Partners L.P. cut its holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 14.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 143,731 shares of the biopharmaceutical company’s stock after selling 24,267 shares during the quarter. Edgestream Partners L.P.’s holdings in Agios Pharmaceuticals were worth $4,862,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Creative Planning raised its position in shares of Agios Pharmaceuticals by 2.2% during the 3rd quarter. Creative Planning now owns 13,119 shares of the biopharmaceutical company’s stock worth $527,000 after purchasing an additional 280 shares during the last quarter. Assetmark Inc. lifted its stake in Agios Pharmaceuticals by 37.9% in the 4th quarter. Assetmark Inc. now owns 1,317 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 362 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in Agios Pharmaceuticals by 0.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 132,083 shares of the biopharmaceutical company’s stock valued at $4,393,000 after buying an additional 512 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in Agios Pharmaceuticals by 26.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,834 shares of the biopharmaceutical company’s stock valued at $77,000 after buying an additional 588 shares during the last quarter. Finally, CANADA LIFE ASSURANCE Co increased its position in Agios Pharmaceuticals by 3.4% during the third quarter. CANADA LIFE ASSURANCE Co now owns 20,325 shares of the biopharmaceutical company’s stock worth $796,000 after buying an additional 662 shares in the last quarter.

Wall Street Analyst Weigh In

AGIO has been the subject of a number of analyst reports. Weiss Ratings reissued a “sell (d)” rating on shares of Agios Pharmaceuticals in a report on Wednesday, June 24th. HC Wainwright upped their price objective on Agios Pharmaceuticals from $52.00 to $55.00 and gave the company a “buy” rating in a research report on Thursday. Bank of America increased their price objective on Agios Pharmaceuticals from $40.00 to $46.00 and gave the company a “buy” rating in a research note on Tuesday, July 7th. Royal Bank Of Canada lifted their price objective on Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a “sector perform” rating in a research report on Tuesday, July 7th. Finally, JPMorgan Chase & Co. cut their target price on shares of Agios Pharmaceuticals from $36.00 to $31.00 and set a “neutral” rating for the company in a research note on Thursday, June 11th. Five investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $40.88.

Agios Pharmaceuticals Stock Performance

Shares of AGIO opened at $30.02 on Friday. Agios Pharmaceuticals, Inc. has a 1 year low of $22.24 and a 1 year high of $46.00. The company’s 50 day simple moving average is $34.48 and its 200 day simple moving average is $30.88. The company has a market capitalization of $1.79 billion, a price-to-earnings ratio of -4.28 and a beta of 0.54.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing the consensus estimate of ($1.65) by ($0.04). The firm had revenue of $44.75 million during the quarter, compared to analysts’ expectations of $26.39 million. Agios Pharmaceuticals had a negative return on equity of 34.40% and a negative net margin of 418.24%. Equities analysts expect that Agios Pharmaceuticals, Inc. will post -6.33 EPS for the current fiscal year.

Key Headlines Impacting Agios Pharmaceuticals

Here are the key news stories impacting Agios Pharmaceuticals this week:

• Positive Sentiment: Second-quarter revenue from mitapivat products Pyrukynd and Aqvesme rose to $44.7 million from $12.5 million a year earlier, helped by Aqvesme’s U.S. launch in thalassemia. The company reported 442 cumulative prescriptions as of June 30. Agios second-quarter financial results
• Positive Sentiment: Agios reported a narrower quarterly loss than the Zacks consensus estimate, while management highlighted continued development of its hematology pipeline. The company also has $964.8 million in cash, cash equivalents and marketable securities to fund commercialization and research programs. Agios Q2 earnings report
• Positive Sentiment: The FDA granted priority review to mitapivat’s supplemental application in sickle cell disease, with a November 1, 2026 decision date. Approval could expand the drug’s addressable market. Agios also expects $45 million to $50 million in 2026 revenue from pyruvate kinase deficiency. Agios revenue outlook and sickle cell review
• Neutral Sentiment: HC Wainwright maintained a Buy rating and a $55 price objective while slightly raising its long-term 2030 EPS forecast. The forecast change supports the longer-term outlook but has limited immediate impact. Agios analyst estimates
• Negative Sentiment: Agios remains deeply unprofitable. Its reported quarterly loss of $1.69 per share was slightly worse than one analyst consensus estimate of $1.65, underscoring continued earnings risk despite revenue growth. Agios earnings results
• Negative Sentiment: Truist lowered its price target from $41 to $39, although it retained a Buy rating. Separately, Pomerantz announced an investigation into potential investor claims, creating an additional headline and legal overhang. Truist price target update

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.